A detailed history of Virtus ETF Advisers LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 9,763 shares of RXRX stock, worth $70,684. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,763
Previous 9,590 1.8%
Holding current value
$70,684
Previous $71,000 9.86%
% of portfolio
0.03%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $1,024 - $1,487
173 Added 1.8%
9,763 $64,000
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $3,652 - $4,994
497 Added 5.47%
9,590 $71,000
Q1 2024

May 15, 2024

SELL
$9.13 - $15.52 $5,678 - $9,653
-622 Reduced 6.4%
9,093 $90,000
Q4 2023

Feb 15, 2024

SELL
$5.09 - $10.79 $1,613 - $3,420
-317 Reduced 3.16%
9,715 $95,000
Q3 2023

Nov 07, 2023

SELL
$6.59 - $15.86 $6,563 - $15,796
-996 Reduced 9.03%
10,032 $76,000
Q2 2023

Aug 14, 2023

SELL
$4.56 - $9.94 $259 - $566
-57 Reduced 0.51%
11,028 $82,000
Q1 2023

May 15, 2023

SELL
$6.42 - $9.64 $27,329 - $41,037
-4,257 Reduced 27.75%
11,085 $73,000
Q4 2022

Feb 14, 2023

SELL
$7.16 - $12.7 $10,775 - $19,113
-1,505 Reduced 8.93%
15,342 $118,000
Q3 2022

Nov 14, 2022

BUY
$7.83 - $13.6 $947 - $1,645
121 Added 0.72%
16,847 $179,000
Q2 2022

Aug 12, 2022

BUY
$5.04 - $9.26 $42,361 - $77,830
8,405 Added 101.01%
16,726 $136,000
Q1 2022

May 16, 2022

SELL
$6.16 - $18.03 $3,080 - $9,015
-500 Reduced 5.67%
8,321 $60,000
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $142,370 - $192,827
8,821 New
8,821 $151,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.31B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.